Prolonged exposure to tenofovir monotherapy 1 month after treatment discontinuation because of tenofovir-related renal failure

Rob Ter Heine; Alwin Dr Huitema; Robert S Jansen; Paul Hm Smits; Eric Cm van Gorp; Jiri Fp Wagenaar; Jos H Beijnen; Jan W Mulder

Prolonged exposure to tenofovir monotherapy 1 month after treatment discontinuation because of tenofovir-related renal failure

Antivir Ther. 2009;14(2):299-301.

Authors

Rob Ter Heine¹, Alwin Dr Huitema, Robert S Jansen, Paul Hm Smits, Eric Cm van Gorp, Jiri Fp Wagenaar, Jos H Beijnen, Jan W Mulder

Affiliation

¹ Department of Pharmacy & Pharmacology, Slotervaart Hospital, Amsterdam, the Netherlands. [email protected]

PMID: 19430105

Abstract

In this study, we present a case of renal failure in a patient who was on a tenofovir-containing regimen, resulting in extremely high tenofovir exposure and prolonged tenofovir monotherapy. We considered this case report important because exposure to tenofovir monotherapy might have consequences for future discontinuation strategies in cases of renal failure.

Publication types

Case Reports

MeSH terms

Adenine / adverse effects
Adenine / analogs & derivatives*
Adenine / pharmacokinetics
Drug Resistance, Viral / drug effects
Drug Therapy, Combination
HIV Infections / complications
HIV Infections / drug therapy*
HIV-1 / drug effects
Hepatitis C, Chronic / complications
Humans
Male
Middle Aged
Organophosphonates / adverse effects
Organophosphonates / pharmacokinetics*
Renal Insufficiency / chemically induced*
Reverse Transcriptase Inhibitors / adverse effects
Reverse Transcriptase Inhibitors / pharmacokinetics
Tenofovir
Time Factors
Withholding Treatment

Substances

Organophosphonates
Reverse Transcriptase Inhibitors
Tenofovir
Adenine